UK Short-Circuits OTC Device Pain Relief Claims For Diabetics, Arthritics
Executive Summary
Ad claims for Actegy's Revitive Circulation Booster device did not rely on clinical evidence that tested the actual product in the way consumers were advised to use it, UK advertising regulator says. Actegy maintained benefits from the device's TENS technology are similar to the effects of NMES technology used in studies it offered as evidence.
You may also be interested in...
GSK Consumer Tries On Wearable Pain Relief With NeuroMetrix Deal
GSK Consumer purchases ex-US rights to pain relief device Quell from NeuroMetrix in a deal that includes co-development of transcutaneous electrical nerve stimulation products.
Industry Roundup: P&G Leadership, Unilever Sale, Ad Claims
Patterson Medical adds Performance Health; EarlySense targets consumer expansion; faster capsule filler available; and more news in brief.
P&G Boosts Guidance Again Despite Dipping 'Consumption Levels' Expected Through June
On a “strong first half of the base,” P&G increased FY2021 guidance for organic sales growth and core earnings per share despite a “sequential deceleration” in US consumption in its categories in December and so far in January.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: